Ospolot: Uses, Dosage & Side Effects

What Is Ospolot and What Is It Used For?

Ospolot contains the active substance sulthiame (also spelled sultiame), a sulfonamide-derived antiepileptic drug that has been in clinical use for more than six decades. Although introduced in the 1960s, sulthiame has been reappraised in recent years thanks to its favorable tolerability in children, its simple twice-daily dosing, and its effectiveness in a specific and very common pediatric epilepsy syndrome. The 20 mg/ml oral suspension makes the medicine particularly suitable for infants, toddlers, and children who cannot yet swallow solid dosage forms, as the dose can be measured precisely with a graduated oral syringe.

At the cellular level, sulthiame is a reversible inhibitor of several isoforms of the enzyme carbonic anhydrase. Carbonic anhydrase catalyses the conversion of carbon dioxide and water to bicarbonate and protons, and this reaction plays an important role in regulating the pH of neurons and glial cells. By inhibiting this enzyme in the brain, sulthiame reduces intracellular bicarbonate, subtly shifting the ionic balance and dampening the neuronal hyperexcitability that underlies epileptic discharges. Beyond carbonic anhydrase inhibition, sulthiame also exerts a stabilizing effect on voltage-gated sodium channels, which contributes to its efficacy in focal epilepsies where high-frequency, synchronized firing of cortical neurons produces seizures.

The most important and best-characterized indication for Ospolot is benign epilepsy of childhood with centrotemporal spikes (BECTS), also called Rolandic epilepsy. This is the single most common focal epilepsy syndrome of childhood, typically beginning between the ages of 3 and 13 years. Affected children often have brief focal motor or sensory seizures during sleep, involving the face, mouth, and throat – sometimes with hypersalivation, speech arrest, and secondary generalization. The EEG shows characteristic sharp waves over the centrotemporal (Rolandic) regions. Although the syndrome is self-limited and almost always remits spontaneously by adolescence, treatment is often considered when seizures are frequent, diurnal, atypical, or associated with cognitive or language difficulties.

Beyond Rolandic epilepsy, Ospolot is used in the treatment of other focal-onset seizures, especially when a child has intolerance or insufficient response to first-line antiepileptic drugs such as carbamazepine, lamotrigine, or levetiracetam. In some countries, sulthiame is also used as an adjunctive therapy in West syndrome (infantile spasms) and in certain rare developmental and epileptic encephalopathies. Its use in generalized tonic-clonic seizures is more limited, and it is not generally considered first-line for absence epilepsy or for epilepsies with predominantly generalized seizures.

Ospolot is approved and marketed in multiple European countries and in several other regions worldwide. Regulatory status and exact approved indications vary between jurisdictions, and in some countries the medicine is available only on a named-patient basis or through specialist prescription channels. In all cases, treatment with sulthiame should be initiated and monitored by a pediatric neurologist or a physician with specific experience in childhood epilepsy, because correct diagnosis of the epilepsy syndrome is essential to appropriate drug selection.

What Should You Know Before Taking Ospolot?

Contraindications

There are a small number of situations in which Ospolot should not be used. These absolute or relative contraindications must be reviewed by the prescribing physician before treatment begins.

• Hypersensitivity: Ospolot must not be given to patients with known hypersensitivity to sulthiame or to any of the excipients in the suspension. Because sulthiame is a sulfonamide, caution is advised in patients with a history of severe allergic reactions to other sulfonamide drugs (including certain antibiotics, thiazide diuretics, and carbonic anhydrase inhibitors), although cross-reactivity is not invariable.
• Acute porphyria: Sulthiame, like several other sulfonamides, may precipitate acute attacks in patients with porphyria and should generally be avoided in these conditions.
• Severe renal impairment: Because sulthiame and its metabolites are eliminated predominantly by the kidneys and because carbonic anhydrase inhibition can worsen metabolic acidosis, severe renal failure is usually considered a contraindication or at least a strong reason to avoid the drug.
• Uncontrolled hyperthyroidism: Sulfonamide carbonic anhydrase inhibitors can affect thyroid function tests, and the drug is typically avoided in uncontrolled hyperthyroidism.
• Severe pulmonary insufficiency: Because sulthiame can induce compensatory hyperpnea, it should be used with caution, or avoided, in children with severe chronic respiratory disease in whom additional changes in breathing pattern could be poorly tolerated.

Warnings and Precautions

Before and during treatment with Ospolot, parents, caregivers, and older children themselves should be aware of the following clinically relevant precautions:

• Metabolic acidosis: Because sulthiame inhibits carbonic anhydrase, it can reduce serum bicarbonate and lead to a mild non-anion-gap metabolic acidosis. In most children this is asymptomatic and clinically insignificant, but it can manifest as hyperpnea (deep breathing), unusual fatigue, or loss of appetite. Children with pre-existing acidosis, severe lung disease, or those on other carbonic anhydrase inhibitors (e.g., acetazolamide, topiramate, zonisamide) are at higher risk.
• Paresthesia: A characteristic class effect of carbonic anhydrase inhibitors is tingling, pricking, or “pins and needles” sensations, typically around the mouth and in the fingers or toes. These sensations are usually mild, dose-dependent, and reversible.
• Kidney function: Sulfonamide drugs can occasionally cause crystalluria or kidney stones, especially if fluid intake is low. Adequate hydration is recommended during treatment. Patients with kidney stones, reduced kidney function, or who are taking other drugs that affect kidney function (e.g., topiramate) should be monitored carefully.
• Skin reactions: As with any sulfonamide, rare but serious skin reactions including erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported. The risk is highest in the first weeks of treatment. Any new widespread rash – especially one with fever, blistering, mucosal ulcers, or skin peeling – requires urgent medical attention and immediate drug discontinuation.
• Behavioral and cognitive effects: Some children experience irritability, hyperactivity, drowsiness, mood changes, or altered sleep, particularly during titration. Learning difficulties and attentional problems should be monitored, and school performance discussed with the family at review visits.
• Suicidal ideation: A small increased risk of suicidal thoughts and behavior has been observed with antiepileptic drugs as a class. Families and caregivers should be alert to mood changes, expressions of hopelessness, or new self-harming thoughts, and report these promptly to the medical team.
• Blood counts: As with many older antiepileptics, rare cases of blood abnormalities (leukopenia, agranulocytosis, thrombocytopenia) have been described. Persistent sore throat, unusual bruising, or unexplained fever should be evaluated with a blood count.
• Liver function: Elevated liver enzymes have occasionally been reported. Periodic liver function monitoring may be considered, especially if clinical symptoms suggest hepatic involvement.
• Pre-existing EEG abnormalities in Dravet syndrome: As with other sodium-channel modulating drugs, caution is advised in children with suspected or confirmed Dravet syndrome or other severe myoclonic epilepsies of infancy, in whom seizures may theoretically be aggravated.

Pregnancy and Breastfeeding

Experience with sulthiame in pregnancy is limited compared with newer antiepileptics. Animal studies have shown some reproductive toxicity at high doses, and controlled human data are insufficient. As with all antiepileptic drugs, untreated seizures during pregnancy also pose a risk to the mother and fetus. If a young woman or adolescent who has been treated with Ospolot becomes pregnant, therapy should not be stopped abruptly; instead, the treating neurologist should be contacted urgently to reassess the balance of risk and benefit and, if appropriate, transition to an antiepileptic with a better-characterized safety profile in pregnancy.

Women of childbearing potential who are prescribed sulthiame should discuss contraception and pregnancy planning with their physician before and during treatment. Folic acid supplementation at doses used for women with epilepsy is generally recommended for those who may become pregnant.

Sulthiame is excreted in breast milk in small amounts. A decision on whether to breastfeed while taking Ospolot should be made on a case-by-case basis with the pediatrician and neurologist, weighing the known benefits of breastfeeding against the theoretical, typically low, risks to the infant. If breastfeeding continues, the infant should be observed for drowsiness, poor feeding, or unusual behavior.

Driving and Operating Machinery

Although Ospolot is used predominantly in children, adolescents and rare adult patients who drive or operate machinery should be aware that sulthiame may cause drowsiness, dizziness, fatigue, or blurred vision, especially at the start of therapy or after dose increases. Patients should not drive or use machinery until they are confident that the medicine does not impair their reaction time or alertness.

Important Information About Ingredients

Ospolot oral suspension contains excipients that may be relevant to some patients. Depending on the exact formulation, these may include sweeteners (such as sucrose, sorbitol, or saccharin), flavorings, preservatives (such as sodium benzoate or parabens), and thickening agents. Parents of children with rare metabolic conditions (e.g., fructose intolerance, galactose intolerance), diabetes, or a history of preservative allergy should review the full list of excipients with the prescribing physician or pharmacist before starting treatment.

How Does Ospolot Interact with Other Drugs?

Drug interactions with sulthiame are clinically important because it is frequently co-prescribed with other antiepileptic drugs in polytherapy and because small changes in plasma levels can translate into significant differences in seizure control or toxicity. The prescribing physician will usually review the complete medication list at every visit and may request periodic plasma level measurements of co-prescribed antiepileptics. Parents and caregivers should always inform the pharmacy and the neurologist when any new medication, including herbal products and dietary supplements, is started or stopped.

Major Interactions

Minor and Other Interactions

Because the precise pharmacokinetic interactions of sulthiame are not as comprehensively characterized as those of newer antiepileptic drugs, specialists often rely on clinical judgment, therapeutic drug monitoring of co-prescribed antiepileptics, and careful observation when introducing or withdrawing other medicines. If the child is prescribed a short course of another medication (for example an antibiotic), the pharmacist should always be made aware of ongoing Ospolot therapy so that potential interactions can be considered.

What Is the Correct Dosage of Ospolot?

Ospolot is almost always administered orally, twice daily, with or shortly after meals to reduce gastrointestinal side effects. The oral suspension must be shaken vigorously before each use so that the active ingredient is evenly dispersed, and the dose should be drawn up with the graduated oral syringe provided by the pharmacy. Approximate dosing examples provided below are educational only; the actual prescription is always individualized by the treating physician on the basis of the child’s body weight, epilepsy syndrome, response, and tolerability.

General Dosing Principles

Because sulthiame has a relatively narrow tolerability window in some children – with paresthesia and hyperpnea being clearly dose-related – a slow, stepwise titration is recommended. The drug is typically started at a low dose, increased gradually over 1 to 2 weeks, and then maintained at the lowest effective dose. Plasma level monitoring is not routinely required for sulthiame itself, but may be useful for co-prescribed antiepileptics (especially phenytoin and primidone). Treatment duration in Rolandic epilepsy is commonly around 2 seizure-free years before a carefully supervised withdrawal is considered.

Adults and Adolescents

Children

Elderly

Sulthiame is rarely used in the elderly and there is limited pharmacokinetic data in older adults. If used, doses should be started at the lower end of the adult range and adjusted cautiously, with particular attention to renal function, concomitant medications, and the risk of metabolic acidosis. Older adults may be more sensitive to dizziness, confusion, and sedation, and may have reduced renal clearance.

Renal and Hepatic Impairment

Because sulthiame is predominantly eliminated by the kidneys, dose reductions and prolonged dosing intervals may be needed in patients with reduced renal function. The drug should generally be avoided in severe renal impairment. In hepatic impairment, dose adjustments are less clearly defined, but cautious titration and clinical monitoring are recommended. Pediatric patients with progressive renal or hepatic disease should be managed in close collaboration with a pediatric neurologist and the relevant organ specialist.

Missed Dose

If a dose of Ospolot is missed, it should be given as soon as the omission is noticed, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doses should not be doubled to make up for a missed dose. If several doses in a row are missed – for example because of vomiting, travel, or forgotten refills – the prescribing team should be contacted for advice on how to safely resume therapy, as reintroduction after a prolonged gap may occasionally require re-titration.

Overdose

Symptoms of sulthiame overdose can include marked hyperpnea, severe paresthesia, drowsiness, confusion, ataxia, vomiting, agitation, and in severe cases seizures or reduced consciousness. Metabolic acidosis may be pronounced. Overdose should be managed as a medical emergency: call the local emergency number or poison control center immediately. Management is supportive and includes maintaining the airway, breathing and circulation, correcting metabolic acidosis, and observing for seizures. There is no specific antidote for sulthiame.

How to Give Ospolot Oral Suspension

To ensure accurate dosing, the following points are important for parents and caregivers administering the suspension at home:

• Shake the bottle vigorously for at least 10-15 seconds before each dose to ensure the active ingredient is evenly dispersed.
• Use only the oral syringe supplied with the medicine; household teaspoons are inaccurate and may deliver too much or too little drug.
• Give the dose with or shortly after food to reduce gastrointestinal side effects and improve palatability.
• Maintain a consistent dosing schedule (for example at breakfast and at bedtime) to help keep drug levels stable and reduce the chance of missed doses.
• Rinse the syringe with water after each use and allow it to dry, to prevent residue buildup.
• Keep a dosing diary or use a medication reminder app, especially during the early titration phase when doses change frequently.

What Are the Side Effects of Ospolot?

Like all medicines, Ospolot can cause side effects, although not every child or patient experiences them. The overall tolerability profile is generally favorable, and many side effects are dose-related and reversible with dose reduction or slower titration. The specific adverse effects observed with sulthiame are largely predictable from its mechanism of action, particularly carbonic anhydrase inhibition.

Most children on Ospolot experience only mild and manageable side effects. Routine follow-up visits typically include review of seizure diaries, school performance, growth parameters, and – if clinically indicated – blood tests for full blood count, liver and kidney function, and bicarbonate levels. Parents and caregivers are encouraged to keep a simple record of new symptoms so that patterns can be recognized early.

Suspected side effects of Ospolot should also be reported to the relevant national pharmacovigilance authority (such as the EMA in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom) to help monitor its ongoing benefit-risk profile.

How Should Ospolot Be Stored?

Correct storage is especially important for liquid antiepileptic medications, because changes in temperature, light exposure, or contamination can affect the stability and safety of the suspension. The following general principles apply unless the product label or the pharmacist provides different instructions for the specific formulation supplied:

• Storage conditions: Keep the bottle tightly closed, upright, at room temperature below 25°C, away from direct sunlight and sources of heat. Do not store in the bathroom, where humidity can be high. Do not freeze.
• Opening date: Write the date of first opening on the bottle label. The in-use shelf life after opening is usually limited – commonly 4-6 weeks – and varies by manufacturer. Any remaining product should be discarded after this period, even if the bottle still contains medicine.
• Child safety: Even when the medicine is intended for a child, the bottle must be stored out of their reach and, where possible, in a locked cupboard. Accidental overdose in siblings or younger children can be serious.
• Travel: When traveling, keep the medicine in its original packaging with the label visible. Consider carrying a copy of the prescription and a medical letter when crossing borders. Avoid leaving the bottle in a hot car.
• Disposal: Do not dispose of unused or expired suspension by pouring it down the sink or into household waste. Return leftover medicine to a pharmacy or follow local environmental guidance. These measures help protect the environment and reduce the risk of medicines reaching unintended users.

If the suspension changes appearance – for example, if it develops an unusual smell, changes color, or cannot be resuspended even after thorough shaking – it should not be used. In this situation, contact the pharmacist for a replacement.

What Does Ospolot Contain?

Active Substance

The active substance is sulthiame (also spelled sultiame), a sulfonamide-derived antiepileptic drug. Each 1 ml of oral suspension contains 20 mg of sulthiame, so the total dose in milligrams can be converted directly into milliliters of the suspension (for example, a 100 mg dose corresponds to 5 ml).

Inactive Ingredients (Excipients)

The precise excipient composition varies between manufacturers and regional presentations, but oral suspensions of sulthiame typically contain:

• A suspending agent or thickener (e.g., xanthan gum, microcrystalline cellulose) to keep the drug evenly dispersed
• A sweetener (e.g., sorbitol, sucrose, or an artificial sweetener such as saccharin or sucralose) to improve palatability for children
• A flavoring (e.g., raspberry, strawberry, or a neutral fruit flavor)
• A preservative (e.g., potassium sorbate, sodium benzoate, or parabens) to prevent microbial growth
• A pH adjuster such as citric acid or sodium citrate
• Purified water as the base

Parents of children with specific dietary requirements, metabolic disorders (such as hereditary fructose intolerance), or sensitivities to particular preservatives should carefully review the package leaflet or discuss the excipient list with the pharmacist before initiating therapy.

Appearance

Ospolot oral suspension is typically a white to off-white, opaque, pourable liquid with a fruit-flavored taste. It is supplied in a multi-dose glass or plastic bottle with a tamper-evident closure, together with an oral dosing syringe and, in many markets, a bottle adapter to facilitate accurate dose withdrawal.

Marketing Authorization Holder

Ospolot is marketed by pharmaceutical companies licensed to distribute sulthiame in the respective country. The exact marketing authorization holder, manufacturing site, and local representative are listed on the package leaflet supplied with the medicine. Availability of the oral suspension may vary by region, and in some countries it is imported as a specialty or orphan medicine under named-patient arrangements.